Non‐small cell lung cancer with mesenchymal–epithelial transition gene exon 14 skipping mutation treated with crizotinib

por Katakura, Seigo, Kobayashi, Nobuaki, Somekawa, Kohei, Masumoto, Nami, Kudo, Makoto, Kaneko, Takeshi
Publicado 2019

Immunohistochemical markers to diagnose primary squamous cell carcinoma of the lung: a meta-analysis of diagnostic test accuracy

por Chen, Hao, Katakura, Seigo, Horita, Nobuyuki, Namkoong, Ho, Kato, Ikuma, Hara, Yu, Kobayashi, Nobuaki, Fujii, Satoshi, Kaneko, Takeshi
Publicado 2022

Class A CpG oligodeoxynucleotide inhibits IFN‐γ‐induced signaling and apoptosis in lung cancer

por Teranishi, Shuhei, Kobayashi, Nobuaki, Katakura, Seigo, Kamimaki, Chisato, Kubo, Sousuke, Shibata, Yuji, Yamamoto, Masaki, Kudo, Makoto, Piao, Hongmei, Kaneko, Takeshi
Publicado 2020

Resistance mechanisms of epidermal growth factor receptor tyrosine kinase inhibitors in non‐small cell lung cancer patients: A meta‐analysis

por Kobayashi, Nobuaki, Katakura, Seigo, Kamimaki, Chisato, Somekawa, Kohei, Fukuda, Nobuhiko, Tanaka, Katsushi, Watanabe, Keisuke, Horita, Nobuyuki, Hara, Yu, Piao, Hongmei, Kaneko, Takeshi
Publicado 2021

The best regimens for chemo-naïve incurable non-squamous non-small cell lung cancer with a programmed death-ligand 1, tumor proportion score 1–49%: a network meta-analysis

por Fukuda, Nobuhiko, Horita, Nobuyuki, Katakura, Seigo, Namkoong, Ho, Kaneko, Ayami, Somekawa, Kouhei, Tagami, Youichi, Watanabe, Keisuke, Hara, Yu, Kobayashi, Nobuaki, Kaneko, Takeshi
Publicado 2021

T‐cell response to phytohemagglutinin in the interferon‐γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non‐small cell lu...

por Kamimaki, Chisato, Kobayashi, Nobuaki, Hirata, Momo, Somekawa, Kohei, Fukuda, Nobuhiko, Kubo, Sousuke, Katakura, Seigo, Teranishi, Shuhei, Watanabe, Keisuke, Horita, Nobuyuki, Hara, Yu, Yamamoto, Masaki, Kudo, Makoto, Piao, Hongmei, Kaneko, Takeshi
Publicado 2021

MicroRNA‐200b is a potential biomarker of the expression of PD‐L1 in patients with lung cancer

por Katakura, Seigo, Kobayashi, Nobuaki, Hashimoto, Hisashi, Kamimaki, Chisato, Tanaka, Katsushi, Kubo, Sousuke, Nakashima, Kentaro, Teranishi, Shuhei, Manabe, Saki, Watanabe, Keisuke, Horita, Nobuyuki, Hara, Yu, Yamamoto, Masaki, Kudo, Makoto, Piao, Hongmei, Kaneko, Takeshi
Publicado 2020

Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial

por Kobayashi, Nobuaki, Hashimoto, Hisashi, Kamimaki, Chisato, Nagasawa, Ryo, Tanaka, Katsushi, Kubo, Sousuke, Katakura, Seigo, Chen, Hao, Hirama, Nobuyuki, Ushio, Ryota, Aoki, Ayako, Nakashima, Kentaro, Teranishi, Shuhei, Manabe, Saki, Watanabe, Hiroki, Horita, Nobuyuki, Watanabe, Keisuke, Hara, Yu, Yamamoto, Masaki, Kudo, Makoto, Piao, Hongmei, Kaneko, Takeshi
Publicado 2020